Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NERVIANO, Italy & SURESNES, France--(BUSINESS WIRE)--Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy, one of the leading oncology-focused, integrated discovery and development companies in Europe, and Servier, a leading research-based European pharmaceutical company today announced a collaboration and worldwide license agreement to further develop and commercialize first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1. A key regulator of mitosis TTK/MPS1 is aberrantly overexpressed in a wide range of tumours and represents a promising target in oncology.
Help employers find you! Check out all the jobs and post your resume.
